Top Markets
Coin of the day
American Oriental Bioengineering, Inc. American Oriental Bioengineering, Inc.

American Oriental Bioengineering, Inc.

AOBI
Rang in Aktien #42790
American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China,... American Oriental Bioengineering, Inc. (AOBI), headquartered in Beijing, China, focuses its operations on the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical and healthcare products. The company's core pharmaceutical offerings include a range of prescription medications. Among these are the Shuanghuanglian Lyophilized Injection Powder (SHL brand), prescribed to treat flu symptoms such as elevated fever, coughs, and sore throats, as well as to address upper respiratory tract infections, mild pneumonia, bronchitis, and tonsillitis. Another significant prescription product is the Cease Enuresis Soft Gel (CE Gel brand), formulated to alleviate bedwetting. AOBI's portfolio also extends to various over-the-counter (OTC) pharmaceutical solutions. These feature the Cease Enuresis Patch for managing bedwetting and urinary incontinence; Jinji Capsule, used for conditions like endometritis, annexitis, and pelvic inflammations; Jinji Yimucao, designed to relieve premenstrual syndrome (PMS) and other related menstrual and menopausal discomforts; and Boke Nasal Spray, which offers relief for sinus congestion associated with the common cold, nasal stuffiness, chronic rhinitis, allergic rhinitis, and nasosinusitis. Furthermore, the company develops and markets a selection of nutraceutical products, notably including soybean peptide-based items available as beverages, tablets, powders, and instant coffee. Beyond its manufacturing activities, AOBI is also involved in the wholesale and retail distribution of both its pharmaceutical and nutraceutical goods. The company's products are sold across the People's Republic of China through both direct channels and a network of distributors, reaching hospitals, clinics, pharmacies, supermarkets, fitness centers, specialty nutraceutical retailers, and various other retail outlets.
Aktienkurs
$0.0012
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$88.00
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
140.00%
Land
CN
Handel American Oriental Bioengineering, Inc. (AOBI)

Kategorie

P/B-Verhältnis für American Oriental Bioengineering, Inc. (AOBI)
P/B-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von American Oriental Bioengineering, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/B-Verhältnis bei 0.
P/B-Verlauf für American Oriental Bioengineering, Inc. von 2026 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
6.2613 -
US
6.3483 -
NL
- -
CH
3.634 -
BE
- -
KR